Lexaria Bioscience has begun dosing in its Human Pilot Study #7, a 5-week trial comparing two oral DehydraTECH-semaglutide formulations to Novo Nordisk's Wegovy® tablets. The study aims to match or exceed the pharmacokinetic performance and safety of Wegovy®, using new tablet and capsule forms with SNAC to improve absorption. This trial is significant as it tests multi-dose, multi-week use of these formulations for the first time, potentially paving the way for commercial partnerships based on Lexaria's proprietary DehydraTECH™ technology. Results will be closely watched by the pharmaceutical industry for future drug delivery innovations.
The global Climate Risk Management Market is projected to grow from $8.59 billion in 2026 to $19.08 billion by 2031, at a CAGR of 17.3%. Growth is fueled by increasing adoption of AI-driven analytics, geospatial intelligence, and cloud-native platfor...
Australia's social commerce market is projected to grow at a 10.6% annual rate, reaching $63.55 billion by 2026 and continuing to $93.38 billion by 2031. Growth is fueled by sectors like clothing, beauty, and electronics, with mobile commerce, video ...
TrendLife's ScamCheck app won the AI Safety Solution of the Year award for its innovative AI-powered scam detection. The app analyzes texts, calls, emails, and websites to identify subtle scam signs, including deepfake videos and multi-step fraud tac...
A webinar on June 30, 2026, hosted by the American Marketing Association and Notified, will discuss how brands can increase visibility in AI-powered search using press releases and earned media. The session will cover practical strategies to optimize...
Jyske Realkredit A/S announced the fixed coupon interest rates for several bond series effective from July 1, 2026, to September 30, 2026. The rates range from 2.31% to 2.92% per annum depending on the bond series. This update informs investors about...
